NO20072501L - Anvendelse av 4-(4-metyopiperazin-1-ylmetyl)-N-[4-metyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid for a inhibere tyrosin kinasereseptor C-FMS - Google Patents
Anvendelse av 4-(4-metyopiperazin-1-ylmetyl)-N-[4-metyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid for a inhibere tyrosin kinasereseptor C-FMSInfo
- Publication number
- NO20072501L NO20072501L NO20072501A NO20072501A NO20072501L NO 20072501 L NO20072501 L NO 20072501L NO 20072501 A NO20072501 A NO 20072501A NO 20072501 A NO20072501 A NO 20072501A NO 20072501 L NO20072501 L NO 20072501L
- Authority
- NO
- Norway
- Prior art keywords
- fms
- ylamino
- benzamide
- pyrimidin
- ylmethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår anvendelse av 4-(4-metylpiperazin-l-ylmetyl)-N-[4-metyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid (også kjent som imatinib, gleevee, glivec, cgp57148b eller 8T1571), eller et farmasøytisk akseptabelt salt av denne, for fremstilling av et medikament for behandling av c-fms-assosierte sykdommer inkludert: koriokarsinom, malign histiocytose, embryonale karsinom, endometrialt karsinom, hjerne mikroblia tumorer, sarkoidose, mikroglia celleinvolvering ved normal og variant Creutzfeld-Jacob sykdom eller amyotrof lateral sklerose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61974404P | 2004-10-18 | 2004-10-18 | |
PCT/AU2005/001602 WO2006042362A1 (en) | 2004-10-18 | 2005-10-17 | Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072501L true NO20072501L (no) | 2007-05-15 |
Family
ID=36202610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072501A NO20072501L (no) | 2004-10-18 | 2007-05-15 | Anvendelse av 4-(4-metyopiperazin-1-ylmetyl)-N-[4-metyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid for a inhibere tyrosin kinasereseptor C-FMS |
Country Status (19)
Country | Link |
---|---|
US (1) | US20080255139A1 (no) |
EP (1) | EP1804800B1 (no) |
JP (1) | JP2008516898A (no) |
KR (1) | KR20070083705A (no) |
CN (1) | CN101035535A (no) |
AT (1) | ATE492277T1 (no) |
AU (1) | AU2005297321A1 (no) |
BR (1) | BRPI0517083A (no) |
CA (1) | CA2580976A1 (no) |
DE (1) | DE602005025514D1 (no) |
IL (1) | IL182419A0 (no) |
MA (1) | MA28946B1 (no) |
MX (1) | MX2007004660A (no) |
NO (1) | NO20072501L (no) |
NZ (1) | NZ554009A (no) |
RU (1) | RU2007118420A (no) |
TN (1) | TNSN07141A1 (no) |
WO (1) | WO2006042362A1 (no) |
ZA (1) | ZA200702316B (no) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2215482A2 (en) * | 2007-10-31 | 2010-08-11 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
EP3789027A1 (en) * | 2015-01-13 | 2021-03-10 | Kyoto University | Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837237A (en) * | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
AU2002342878A1 (en) * | 2001-05-16 | 2002-11-25 | Axxima Pharmaceuticals Ag | Pyridylpyrimidine derivatives as effective compounds against prion diseases |
WO2004026930A2 (en) * | 2002-06-26 | 2004-04-01 | The Ohio State University Research Foundation | The method for reducing inflammation using sti-571 or its salt |
-
2005
- 2005-10-17 US US11/576,967 patent/US20080255139A1/en not_active Abandoned
- 2005-10-17 KR KR1020077008716A patent/KR20070083705A/ko not_active Application Discontinuation
- 2005-10-17 AT AT05793868T patent/ATE492277T1/de not_active IP Right Cessation
- 2005-10-17 BR BRPI0517083-4A patent/BRPI0517083A/pt not_active IP Right Cessation
- 2005-10-17 DE DE602005025514T patent/DE602005025514D1/de active Active
- 2005-10-17 WO PCT/AU2005/001602 patent/WO2006042362A1/en active Application Filing
- 2005-10-17 JP JP2007535954A patent/JP2008516898A/ja active Pending
- 2005-10-17 AU AU2005297321A patent/AU2005297321A1/en not_active Abandoned
- 2005-10-17 CN CNA2005800338341A patent/CN101035535A/zh active Pending
- 2005-10-17 CA CA002580976A patent/CA2580976A1/en not_active Abandoned
- 2005-10-17 MX MX2007004660A patent/MX2007004660A/es unknown
- 2005-10-17 EP EP05793868A patent/EP1804800B1/en active Active
- 2005-10-17 RU RU2007118420/15A patent/RU2007118420A/ru unknown
- 2005-10-17 NZ NZ554009A patent/NZ554009A/en not_active IP Right Cessation
-
2007
- 2007-03-20 ZA ZA200702316A patent/ZA200702316B/xx unknown
- 2007-04-10 IL IL182419A patent/IL182419A0/en unknown
- 2007-04-17 TN TNP2007000141A patent/TNSN07141A1/fr unknown
- 2007-04-25 MA MA29848A patent/MA28946B1/fr unknown
- 2007-05-15 NO NO20072501A patent/NO20072501L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2007004660A (es) | 2007-10-17 |
TNSN07141A1 (en) | 2008-11-21 |
US20080255139A1 (en) | 2008-10-16 |
AU2005297321A1 (en) | 2006-04-27 |
ZA200702316B (en) | 2008-09-25 |
EP1804800A4 (en) | 2008-03-19 |
EP1804800A1 (en) | 2007-07-11 |
ATE492277T1 (de) | 2011-01-15 |
IL182419A0 (en) | 2007-09-20 |
BRPI0517083A (pt) | 2008-09-30 |
EP1804800B1 (en) | 2010-12-22 |
RU2007118420A (ru) | 2008-11-27 |
NZ554009A (en) | 2010-09-30 |
MA28946B1 (fr) | 2007-10-01 |
WO2006042362A1 (en) | 2006-04-27 |
JP2008516898A (ja) | 2008-05-22 |
KR20070083705A (ko) | 2007-08-24 |
CA2580976A1 (en) | 2006-04-27 |
CN101035535A (zh) | 2007-09-12 |
DE602005025514D1 (de) | 2011-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1332137E (pt) | Tratamento de tumores estromais gastrintestinais | |
PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
TWI347186B (en) | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
PE20121476A1 (es) | Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r | |
RS54608B1 (en) | CGRP RECEPTOR ANTAGONITY | |
HUE034712T2 (hu) | Amidszármazék és gyógyszer | |
EA201070366A1 (ru) | 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы | |
WO2008059551A3 (en) | Process for the preparation of imatinib and intermediates thereof | |
NO20075022L (no) | (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav | |
BR0312873A (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante | |
NZ590177A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
HRP20100265T1 (hr) | Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti | |
JP2008542390A5 (no) | ||
NO20072501L (no) | Anvendelse av 4-(4-metyopiperazin-1-ylmetyl)-N-[4-metyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid for a inhibere tyrosin kinasereseptor C-FMS | |
ATE524171T1 (de) | Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit | |
MA35636B1 (fr) | Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide | |
NO20056188L (no) | Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes | |
IL162983A (en) | Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis | |
AU2003216621A8 (en) | Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer | |
RU2020127993A (ru) | Терапевтическое средство для лечения гепатоцеллюлярной карциномы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |